- 3.4Impact Factor
- 9.9CiteScore
- 20 daysTime to First Decision
Vaccines, Volume 8, Issue 4
December 2020 - 228 articles
Cover Story: A human or nonhuman adenoviral (Ad) vector-based vaccine platform is a versatile egg-independent and cost-effective approach for generating large numbers of influenza vaccine doses in a short timeframe. The activation of innate immunity by the Ad vector induces broad, durable, and protective influenza-specific humoral and cell-mediated immune responses. Due to the availability of less-prevalent human Ad vectors and nonhuman Ad vectors as vaccine platforms, there will be a minimal impact of preexisting Ad vector immunity on vaccine efficacy. An Ad vector-based vaccine platform is well suited for designing effective vaccines not only for seasonal and pandemic influenza but also for other infectious diseases. View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles
There are no articles in this issue yet.
Get Alerted
Add your email address to receive forthcoming issues of this journal.
Vaccines - ISSN 2076-393XCreative Common CC BY license